avi-6003

Nucleic acidexperimental

Clinical trial activity

1 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2011 (NCT01353040)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • MarburgvirusANTISENSE INHIBITOR

    Marburgvirus antisense inhibitor

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • avi-6003

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01353040Phase 1May 1, 2011Department of Defense, Sarepta Therapeutics, WCCT Global
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Department of DefenseGovernment1012011
Sarepta TherapeuticsFor profit1112011
WCCT GlobalFor profit1012011
3 organizations
Page 1 / 1